COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES

Objective: To compare the metabolic outcomes in psychiatric patients treated with Olanzapine and Risperidone. Study Design: Quasi experimental study. Place and Duration of Study: The study was conducted at Armed Forces Institute of Mental Health, Rawalpindi, from Aug 2016 to Jan 2017. Meth...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shiraz Hussain, Nomita Imtiaz, Malik Awais Amin, Sana Khan, Siddique Kakar
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2021
Materias:	metabolic syndrome (mets) hyperglycemia dyslipidemia atypical antipsychotics Medicine R Medicine (General) R5-920
Acceso en línea:	https://doi.org/10.51253/pafmj.v71iSuppl-1.3382 https://doaj.org/article/caf6320e2a4d483b9f2ba2581e951a0d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:caf6320e2a4d483b9f2ba2581e951a0d
record_format	dspace
spelling	oai:doaj.org-article:caf6320e2a4d483b9f2ba2581e951a0d2021-12-02T19:11:56ZCOMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMEShttps://doi.org/10.51253/pafmj.v71iSuppl-1.33820030-96482411-8842https://doaj.org/article/caf6320e2a4d483b9f2ba2581e951a0d2021-01-01T00:00:00Zhttps://pafmj.org/index.php/PAFMJ/article/view/3382https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To compare the metabolic outcomes in psychiatric patients treated with Olanzapine and Risperidone. Study Design: Quasi experimental study. Place and Duration of Study: The study was conducted at Armed Forces Institute of Mental Health, Rawalpindi, from Aug 2016 to Jan 2017. Methodology: In this study 114 newly diagnosed psychiatric patients taking atypical anti-psychotics were selected and placed randomly into two groups i.e. group A (Olanzapine) andgroup B (Risperidone), 57 patients each. Patients of either gender, 20 to 60 years’ age, clinically diagnosed new cases having psychiatric illness using DSMV were selected consecutively. Baseline and six months’ end study data were collected and compared. Results: Total 14 out of 109 (5 patients lost follow up) patients developed metabolic syndrome. Among these 10 (18.18%) were in group A while 4 (7.41%) were in group B. Patients receiving Olanzapine were 2.58 times more prone to develop metabolic syndrome compared to the Risperidone receiving [RR= 2.58 {C.I. 0.85009, 7.62703}]. Weight gain (p-value = 0.0048), increased Waist circumference (p-value = 0.00867) and elevated Blood Pressure (pvalue = 0.0563) were seen more significantly with use of Olanzapine. Conclusion: Olanzapine although associated with good efficacy but indeed with more serious and long-term side effects like impaired blood glucose tolerance, dyslipidemia and increase weight. Psychiatrist must screen and continuously monitor such patients.Shiraz HussainNomita ImtiazMalik Awais AminSana KhanSiddique KakarArmy Medical College Rawalpindiarticlemetabolic syndrome(mets)hyperglycemiadyslipidemiaatypical antipsychoticsMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 71, Iss SUPPL-1, Pp 147-152 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	metabolic syndrome (mets) hyperglycemia dyslipidemia atypical antipsychotics Medicine R Medicine (General) R5-920
spellingShingle	metabolic syndrome (mets) hyperglycemia dyslipidemia atypical antipsychotics Medicine R Medicine (General) R5-920 Shiraz Hussain Nomita Imtiaz Malik Awais Amin Sana Khan Siddique Kakar COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES
description	Objective: To compare the metabolic outcomes in psychiatric patients treated with Olanzapine and Risperidone. Study Design: Quasi experimental study. Place and Duration of Study: The study was conducted at Armed Forces Institute of Mental Health, Rawalpindi, from Aug 2016 to Jan 2017. Methodology: In this study 114 newly diagnosed psychiatric patients taking atypical anti-psychotics were selected and placed randomly into two groups i.e. group A (Olanzapine) andgroup B (Risperidone), 57 patients each. Patients of either gender, 20 to 60 years’ age, clinically diagnosed new cases having psychiatric illness using DSMV were selected consecutively. Baseline and six months’ end study data were collected and compared. Results: Total 14 out of 109 (5 patients lost follow up) patients developed metabolic syndrome. Among these 10 (18.18%) were in group A while 4 (7.41%) were in group B. Patients receiving Olanzapine were 2.58 times more prone to develop metabolic syndrome compared to the Risperidone receiving [RR= 2.58 {C.I. 0.85009, 7.62703}]. Weight gain (p-value = 0.0048), increased Waist circumference (p-value = 0.00867) and elevated Blood Pressure (pvalue = 0.0563) were seen more significantly with use of Olanzapine. Conclusion: Olanzapine although associated with good efficacy but indeed with more serious and long-term side effects like impaired blood glucose tolerance, dyslipidemia and increase weight. Psychiatrist must screen and continuously monitor such patients.
format	article
author	Shiraz Hussain Nomita Imtiaz Malik Awais Amin Sana Khan Siddique Kakar
author_facet	Shiraz Hussain Nomita Imtiaz Malik Awais Amin Sana Khan Siddique Kakar
author_sort	Shiraz Hussain
title	COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES
title_short	COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES
title_full	COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES
title_fullStr	COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES
title_full_unstemmed	COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES
title_sort	comparison of two widely used atypical antipsychotics olanzapine versus risperidone in terms of metabolic outcomes
publisher	Army Medical College Rawalpindi
publishDate	2021
url	https://doi.org/10.51253/pafmj.v71iSuppl-1.3382 https://doaj.org/article/caf6320e2a4d483b9f2ba2581e951a0d
work_keys_str_mv	AT shirazhussain comparisonoftwowidelyusedatypicalantipsychoticsolanzapineversusrisperidoneintermsofmetabolicoutcomes AT nomitaimtiaz comparisonoftwowidelyusedatypicalantipsychoticsolanzapineversusrisperidoneintermsofmetabolicoutcomes AT malikawaisamin comparisonoftwowidelyusedatypicalantipsychoticsolanzapineversusrisperidoneintermsofmetabolicoutcomes AT sanakhan comparisonoftwowidelyusedatypicalantipsychoticsolanzapineversusrisperidoneintermsofmetabolicoutcomes AT siddiquekakar comparisonoftwowidelyusedatypicalantipsychoticsolanzapineversusrisperidoneintermsofmetabolicoutcomes
_version_	1718377116102295552

COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES

Ejemplares similares